J. Lawrence

发表

Highly active antiretroviral therapy results in HIV type 1 suppression in lymph nodes, increased pools of naive T cells, decreased pools of activated T cells, and diminished frequencies of peripheral activated HIV type 1-specific CD8+ T cells.

T. Merigan, J. Schapiro, C. Gray, 2000, AIDS research and human retroviruses.

Human Immunodeficiency Virus Type 1 Protease Genotypes and In Vitro Protease Inhibitor Susceptibilities of Isolates from Individuals Who Were Switched to Other Protease Inhibitors after Long-Term Saquinavir Treatment

T. Merigan, J. Schapiro, J. Lawrence, 1998, Journal of Virology.

Resistance mutations to zidovudine and saquinavir in patients receiving zidovudine plus saquinavir or zidovudine and zalcitabine plus saquinavir in AIDS clinical trials group 229.

B. Efron, T. Merigan, J. Schapiro, 1999, The Journal of infectious diseases.

Concomitant administration of diphtheria, tetanus, acellular pertussis and inactivated poliovirus vaccine derived from Sabin strains (DTaP-sIPV) with pentavalent rotavirus vaccine in Japanese infants

J. Lawrence, J. Stek, Yoshiyuki Tanaka, 2017, Human vaccines & immunotherapeutics.

Safety and immunogenicity of pentavalent rotavirus vaccine in a randomized, double-blind, placebo-controlled study in healthy elderly subjects

J. Lawrence, F. Schödel, M. Ciarlet, 2014, Human vaccines & immunotherapeutics.

Safety and immunogenicity of a live attenuated pentavalent rotavirus vaccine in HIV-exposed infants with or without HIV infection in Africa

J. Lawrence, J. Lindsey, M. Levin, 2017, AIDS.

Human P[6] Rotaviruses From Sub-Saharan Africa and Southeast Asia Are Closely Related to Those of Human P[4] and P[8] Rotaviruses Circulating Worldwide.

J. Matthijnssens, M. Van Ranst, J. Lawrence, 2016, The Journal of infectious diseases.

Differences in Reversion of Resistance Mutations to Wild-Type under Structured Treatment Interruption and Related Increase in Replication Capacity

J. Lawrence, C. Chappey, R. Kim, 2011, PloS one.

Receiving Highly Active Antiretroviral T Cells in Individuals + Anti-HIV CD 8 Frequency of Class I HLA-Restricted

Mark M. Davis, J. Schapiro, C. Gray, 1999 .

Risk Factors for Primary Clostridium difficile Infection; Results From the Observational Study of Risk Factors for Clostridium difficile Infection in Hospitalized Patients With Infective Diarrhea (ORCHID)

J. Lawrence, B. Gärtner, M. Wilcox, 2020, Frontiers in Public Health.

Frequency of class I HLA-restricted anti-HIV CD8+ T cells in individuals receiving highly active antiretroviral therapy (HAART).

T. Merigan, J. Schapiro, C. Gray, 1999, Journal of immunology.

Lopinavir/Ritonavir Affects Pharmacokinetic Exposure of Artemether/Lumefantrine in HIV-Uninfected Healthy Volunteers

P. Rosenthal, D. Havlir, J. Lawrence, 2009, Journal of acquired immune deficiency syndromes.

A randomized comparison of two instruments for measuring self-reported antiretroviral adherence

A. Wu, J. Lawrence, M. Chesney, 2008, AIDS care.

Comparative analysis of pentavalent rotavirus vaccine strains and G8 rotaviruses identified during vaccine trial in Africa

J. Matthijnssens, M. Van Ranst, J. Lawrence, 2015, Scientific Reports.

A Multi-Investigator/Institutional DNA Bank for AIDS-Related Human Genetic Studies: AACTG Protocol A5128

David W. Haas, Douglas D. Richman, Margaret A. Matula, 2003, HIV clinical trials.

Structured treatment interruptions (STI) in chronic unsuppressed HIV infection in adults.

J. Lawrence, A. Reingold, J. Tulsky, 2006, The Cochrane database of systematic reviews.

Prevalence and Impact of HIV-1 Protease Codon 33 Mutations and Polymorphisms in Treatment-Naive and Treatment-Experienced Patients

M. Kozal, J. Lawrence, K. H. Hullsiek, 2005, Antiviral therapy.

Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus.

Gary Collins, J. Lawrence, K. H. Hullsiek, 2003, The New England journal of medicine.

A randomized, partially blinded phase 2 trial of antiretroviral therapy, HIV-specific immunizations, and interleukin-2 cycles to promote efficient control of viral replication (ACTG A5024).

J. Lawrence, A. Zolopa, R. Bosch, 2006, The Journal of infectious diseases.

A retrospective study to determine if hydroxyurea augmentation of antiretroviral drug regimens that contain ddI and/or d4T increases the risk of developing peripheral neuropathy in HIV‐1 infected individuals

J. Lawrence, W. Mccarthy, J. Gable, 2000, Pharmacoepidemiology and drug safety.

Efficacy and safety of pentavalent rotavirus vaccine in Japan

J. Lawrence, S. Iwata, M. Brown, 2013, Human vaccines & immunotherapeutics.

Disadvantages of Structured Treatment Interruption Persist in Patients With Multidrug-Resistant HIV-1: Final Results of the CPCRA 064 Study

J. Lawrence, K. H. Hullsiek, D. Abrams, 2006, Journal of acquired immune deficiency syndromes.

Safety and immunogenicity of different Clostridioides (Clostridium) difficile vaccine formulations in two early phase randomized studies of healthy adults aged 50-85 years.

J. Lawrence, N. Kitchin, K. Jansen, 2021, Vaccine.

Clinical resistance patterns and responses to two sequential protease inhibitor regimens in saquinavir and reverse transcriptase inhibitor-experienced persons.

B. Efron, T. Merigan, J. Schapiro, 1999, The Journal of infectious diseases.

Clinical cross-resistance between the HIV-1 protease inhibitors saquinavir and indinavir and correlations with genotypic mutations.

T. Merigan, J. Schapiro, J. Lawrence, 1999, AIDS.

Structured treatment interruptions (STI) in chronic suppressed HIV infection in adults.

J. Lawrence, J. Colford, A. Reingold, 2005, The Cochrane database of systematic reviews.

A study of RotaTeq™ (pentavalent rotavirus vaccine) in Chinese healthy adults, children and infants

J. Lawrence, C. Shen, Rong-cheng Li, 2012 .

A randomized comparison of two instruments for measuring self-reported antiretroviral adherence

A. Wu, J. Lawrence, M. Chesney, 2008, AIDS care.

A Risk Score to Predict Clostridioides difficile Infection

E. Lewis, J. Lawrence, B. Fireman, 2021, Open forum infectious diseases.